It is not recommended for those who have a BMI of less than 30 kg/m2, or 27 kg/m2 with an underlying health condition that is directly correlated to their weight
Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs
Helping with weight loss Some GLP-1 agonists are specifically manufactured and FDA-approved and prescribed for weight loss
TIRZEPATIDES THICKET OF FOLLOW-ON PATENTS Eli Lilly has built a thicket of follow-on patents in addition to the patent protecting the main compound tirzepatide (Figure 9)
For example, Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.* A persons medical history and health goals will also need to be taken into consideration
Additional tests can assess the severity of the condition and determine the best course of treatment